05/15/2025
4:44 PM | 4D Molecular Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SCHEDULE 13G/A | |
05/08/2025
3:33 PM | 4D Molecular Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
04/29/2025
3:10 PM | 4D Molecular Therapeutics (Filer)
| Form ARS | |
03/24/2025
11:15 PM | 4D Molecular Therapeutics (Filer)
| Form EFFECT | |
03/10/2025
6:56 PM | 4D Molecular Therapeutics (Issuer)
Kamal Fariborz (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/10/2025
6:57 PM | 4D Molecular Therapeutics (Issuer)
Mehra Uneek (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/10/2025
6:58 PM | 4D Molecular Therapeutics (Issuer)
Kim Robert Young (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/10/2025
6:58 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/10/2025
7:00 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/28/2025
3:57 PM | 4D Molecular Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/28/2025
4:07 PM | 4D Molecular Therapeutics (Filer)
| Form POS AM | |
Get the Latest News and Ratings for FDMT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
02/14/2025
5:30 PM | 4D Molecular Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SCHEDULE 13G/A | |
02/14/2025
5:09 PM | 4D Molecular Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SCHEDULE 13G/A | |
02/14/2025
10:34 AM | 4D Molecular Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SCHEDULE 13G/A | |
02/14/2025
7:40 AM | 4D Molecular Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
| Form SCHEDULE 13G/A | |
02/10/2025
4:28 PM | 4D Molecular Therapeutics (Subject)
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
| Form SCHEDULE 13G/A | |
02/10/2025
7:37 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/10/2025
7:36 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/11/2024
3:15 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/15/2024
4:05 PM | 4D Molecular Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
4:46 PM | 4D Molecular Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
2:15 PM | 4D Molecular Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
11/14/2024
8:13 AM | 4D Molecular Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
| Form SC 13G/A | |
11/13/2024
3:33 PM | 4D Molecular Therapeutics (Issuer)
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/13/2024
3:17 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/13/2024
3:08 PM | 4D Molecular Therapeutics (Subject)
BIOTECHNOLOGY VALUE FUND L P (Filed by)
| Form SC 13G/A | |
11/12/2024
11:12 AM | 4D Molecular Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/08/2024
1:17 PM | 4D Molecular Therapeutics (Subject)
BlackRock, Inc. (Filed by)
| Form SC 13G/A | |
11/06/2024
5:07 PM | 4D Molecular Therapeutics (Subject)
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
| Form SC 13G | |
11/04/2024
9:55 AM | 4D Molecular Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G | |
10/21/2024
3:11 PM | 4D Molecular Therapeutics (Subject)
BlackRock, Inc. (Filed by)
| Form SC 13G/A | |
09/18/2024
4:46 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
3:06 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/23/2024
5:04 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
7:22 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/17/2024
5:04 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/15/2024
5:13 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:46 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/10/2024
4:17 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2024
4:11 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/01/2024
3:43 PM | 4D Molecular Therapeutics (Subject)
Bizily Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
[No Brainer Gold Play]: “Show me a better investment.” (Ad) A Historic Gold Announcement Is About to Rock Wall Street?
For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains. Click here to get Garrett’s Top Four picks now. |
06/26/2024
4:07 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/25/2024
3:44 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144/A | |
06/24/2024
4:39 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
